IL245088A0 - A chimeric receptor that causes antibody-dependent cytotoxicity for multiple tumors - Google Patents

A chimeric receptor that causes antibody-dependent cytotoxicity for multiple tumors

Info

Publication number
IL245088A0
IL245088A0 IL245088A IL24508816A IL245088A0 IL 245088 A0 IL245088 A0 IL 245088A0 IL 245088 A IL245088 A IL 245088A IL 24508816 A IL24508816 A IL 24508816A IL 245088 A0 IL245088 A0 IL 245088A0
Authority
IL
Israel
Prior art keywords
dependent cell
chimeric receptor
cell cytotoxicity
against multiple
cytotoxicity against
Prior art date
Application number
IL245088A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Singapore
St Jude Childrens Res Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Singapore, St Jude Childrens Res Hospital filed Critical Univ Singapore
Publication of IL245088A0 publication Critical patent/IL245088A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL245088A 2013-10-17 2016-04-13 A chimeric receptor that causes antibody-dependent cytotoxicity for multiple tumors IL245088A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892218P 2013-10-17 2013-10-17
US201462026243P 2014-07-18 2014-07-18
PCT/US2014/060999 WO2015058018A1 (en) 2013-10-17 2014-10-17 Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors

Publications (1)

Publication Number Publication Date
IL245088A0 true IL245088A0 (en) 2016-06-30

Family

ID=52828713

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245088A IL245088A0 (en) 2013-10-17 2016-04-13 A chimeric receptor that causes antibody-dependent cytotoxicity for multiple tumors

Country Status (11)

Country Link
EP (1) EP3057986B1 (enExample)
JP (1) JP6417413B2 (enExample)
KR (1) KR102308597B1 (enExample)
CN (1) CN105683214B (enExample)
AU (1) AU2014337195B2 (enExample)
BR (1) BR112016007695A2 (enExample)
CA (1) CA2926267C (enExample)
IL (1) IL245088A0 (enExample)
SG (1) SG11201602979RA (enExample)
WO (1) WO2015058018A1 (enExample)
ZA (1) ZA201602798B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
MX2017003062A (es) * 2014-09-09 2017-12-14 Unum Therapeutics Receptores quimericos y usos de los mismos en terapia inmune.
RU2017142352A (ru) 2015-05-06 2019-06-06 Снипр Текнолоджиз Лимитед Изменение популяций микроорганизмов и модификация микробиоты
CN108138171B (zh) * 2015-10-08 2022-05-13 国立大学法人名古屋大学 表达嵌合抗原受体的基因修饰t细胞的制备方法
TW201732037A (zh) * 2015-10-15 2017-09-16 安瑟吉納西斯公司 自然殺手細胞及ilc3細胞及其用途
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3487877A4 (en) * 2016-07-19 2020-01-01 Unum Therapeutics Inc. USE OF THE ANTIBODY COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE CANCER ANTIBODIES IN THE TREATMENT OF CANCER
EP3315511A1 (en) 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
US11440958B2 (en) 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
WO2019056174A1 (zh) * 2017-09-19 2019-03-28 中山大学 一种过表达cxcr5的间质干细胞及其制备方法和用途
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2019222642A1 (en) * 2018-05-18 2019-11-21 Senti Biosciences, Inc. Engineered immune cells and methods of use
JP2021524467A (ja) * 2018-05-23 2021-09-13 メニスマート セラピューティクス， インコーポレイテッドＭａｎｙｓｍａｒｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 二重特異性ｔ細胞誘導体及びその使用
CN112638402A (zh) 2018-07-03 2021-04-09 Sotio有限责任公司 与增强葡萄糖输入的反式代谢分子组合的嵌合受体及其治疗用途
IL280322B2 (en) 2018-08-14 2025-06-01 Sotio Llc Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
EP3620464A1 (en) 2018-09-10 2020-03-11 Miltenyi Biotec GmbH Car cell having crosslinked disulfide bridge on antigen recognizing moiety
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US20220193137A1 (en) 2019-04-04 2022-06-23 Umc Utrecht Holding B.V. Modified immune receptor constructs
WO2021047804A1 (en) 2019-09-11 2021-03-18 Miltenyi Biotec B.V. & Co. KG In vitro method for transduction of t cells in the presence of malignant cells
EP3875478A1 (en) 2020-03-05 2021-09-08 Canvax Biotech, S.L. Novel non-immunogenic chimeric antigen receptors and uses thereof
EP3878464A1 (en) 2020-03-09 2021-09-15 Miltenyi Biotec B.V. & Co. KG Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
CN113583139A (zh) * 2020-07-06 2021-11-02 上海鑫湾生物科技有限公司 一种嵌合受体及其应用
KR20240069799A (ko) 2021-09-27 2024-05-20 소티오 바이오테크 인크. 해당과정 경로 밖으로 포도당 대사산물을 재지향시키는 트랜스 대사 분자와 조합되는 키메라 수용체 폴리펩타이드 및 이의 치료적 용도
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
EP4572787A1 (en) 2022-08-19 2025-06-25 SOTIO Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JPH09501055A (ja) 1993-07-30 1997-02-04 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー 初代リンパ球への効率的遺伝子転移
WO2003101485A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
US20080003225A1 (en) * 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
CA2694055A1 (en) * 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
US8067339B2 (en) * 2008-07-09 2011-11-29 Merck Sharp & Dohme Corp. Surface display of whole antibodies in eukaryotes
DE102009013748B4 (de) 2009-03-17 2012-01-26 Paul-Ehrlich-Institut Bestimmung von Interaktionen konstanter Antikörperteile mit Fc-gamma Rezeptoren
US8465743B2 (en) * 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US20140072983A1 (en) 2010-08-10 2014-03-13 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2017003062A (es) 2014-09-09 2017-12-14 Unum Therapeutics Receptores quimericos y usos de los mismos en terapia inmune.

Also Published As

Publication number Publication date
EP3057986A1 (en) 2016-08-24
BR112016007695A2 (pt) 2017-09-12
AU2014337195A1 (en) 2016-04-21
WO2015058018A1 (en) 2015-04-23
CA2926267C (en) 2023-08-01
EP3057986A4 (en) 2017-03-15
CA2926267A1 (en) 2015-04-23
CN105683214B (zh) 2021-03-09
AU2014337195B2 (en) 2018-11-08
KR20160062762A (ko) 2016-06-02
JP2016534717A (ja) 2016-11-10
SG11201602979RA (en) 2016-05-30
JP6417413B2 (ja) 2018-11-07
EP3057986B1 (en) 2017-12-27
ZA201602798B (en) 2018-12-19
CN105683214A (zh) 2016-06-15
KR102308597B1 (ko) 2021-10-01

Similar Documents

Publication Publication Date Title
ZA201602798B (en) Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
IL244784A0 (en) chimeric antigen receptor
GB201309236D0 (en) Delay adjustment
EP3009049A4 (en) SEAT WARMER
IL239774A0 (en) feed network
IL240687A0 (en) Ganglioside preparations
GB201315399D0 (en) Heater
GB201304803D0 (en) Videoconferencing
GB2530691B (en) Radiation imaging
GB2513316B (en) Wedge mechanism
GB201309095D0 (en) Locking mechanism
GB2519212B (en) Locking mechanism
GB2522602B (en) Locking mechanism
PL2850975T3 (pl) Okucie oparcia
GB2516476B (en) Toaster
SG11201510197RA (en) Connecting Mechanism
IL230195A0 (en) spacing mechanism
AU353529S (en) Toaster
GB201308400D0 (en) Anti-ligature mechanism
GB201315719D0 (en) The back station
GB201302364D0 (en) Seats
HK1226776A1 (en) Chimeric polynucleotides
GB201320647D0 (en) Immunoconjugates
GB201318043D0 (en) Immunoconjugates
GB201307081D0 (en) Combines